Compare CLSK & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLSK | TLX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 2008 | N/A |
| Metric | CLSK | TLX |
|---|---|---|
| Price | $11.27 | $10.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $19.44 | ★ $21.13 |
| AVG Volume (30 Days) | ★ 17.4M | 210.3K |
| Earning Date | 05-07-2026 | 04-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $766,314,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.89 | N/A |
| P/E Ratio | ★ N/A | $150.33 |
| Revenue Growth | ★ 102.21 | N/A |
| 52 Week Low | $7.03 | $6.28 |
| 52 Week High | $23.61 | $19.93 |
| Indicator | CLSK | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 63.98 | 69.19 |
| Support Level | $8.78 | $10.60 |
| Resistance Level | $14.04 | $11.18 |
| Average True Range (ATR) | 0.70 | 0.32 |
| MACD | 0.27 | 0.14 |
| Stochastic Oscillator | 84.11 | 70.36 |
Cleanspark Inc. is a data center developer that, until recently, focused exclusively on bitcoin mining. The company provides scalable, energy-efficient digital infrastructure across the United States. The Company has a sole reporting segment, which is the bitcoin mining segment.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.